Cell engineering

Telesis Bio and Cellibre Announce Collaboration to Optimize Development of Future BioXp® DBC instrument

Retrieved on: 
Wednesday, October 19, 2022
SAN, U.S. Securities and Exchange Commission, RNA transfection, SEC, Cell engineering, Agriculture, Laboratory, Synthetic biology, Biology, RNA, Codex, Security (finance), Cell, Immortalised cell line, EDS, Partnership, Technology, Automation, Precision medicine, Solution, Private Securities Litigation Reform Act, Company, 9600, Doctor of Philosophy, Reading, CEO, Ecosystem, CRISPR, DBC, GLOBE, Forward-looking statement, Gibson, DNA, Invention, Digital, Fine chemical, Telesis

The gRNA synthesis kit is the first of several BioXp DBC kits the company has planned.

Key Points: 
  • The gRNA synthesis kit is the first of several BioXp DBC kits the company has planned.
  • Our deep and long-standing partnership with Telesis Bio will enhance and expand their highly automated solutions for synthetic biology applications, said Ben Chiarelli, CEO of Cellibre.
  • We look forward to working with the Cellibre team to validate and enhance our automated BioXp DBC solution for generating CRISPR-Cas9 guide RNA on demand.
  • Telesis Bio is empowering scientists with the ability to create novel, synthetic biology-enabled solutions for many of humanitys greatest challenges.

Eterna Therapeutics to Present at iPSC-Derived Immunotherapies Congress

Retrieved on: 
Tuesday, October 18, 2022
SAN, Method, U.S. Securities and Exchange Commission, Congress, Securities Act of 1933, Communication, RNA transfection, ERNA, Growth, Cell engineering, Annual report, Patient, Gene editing, Nasdaq, Technology, Private Securities Litigation Reform Act, Company, Securities Exchange Act of 1934, GLOBE, Interim, Forward-looking statement, Terminology, COVID-19, Sumathi Best Television Current Reporting Award, Pharmaceutical industry, Eterna

SAN DIEGO, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (Eterna or the Company), a biopharmaceutical company using advanced cell engineering technology to develop transformational new medicines, today announced that Matt Angel, Ph.D., Interim Chief Executive Officer of Eterna, will present at the iPSC-Derived Immunotherapies Congress, taking place October 18-19, 2022 in Boston.

Key Points: 
  • SAN DIEGO, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (Eterna or the Company), a biopharmaceutical company using advanced cell engineering technology to develop transformational new medicines, today announced that Matt Angel, Ph.D., Interim Chief Executive Officer of Eterna, will present at the iPSC-Derived Immunotherapies Congress, taking place October 18-19, 2022 in Boston.
  • Location: Hilton Boston Back Bay Hotel, 40 Dalton St., Boston, Massachusetts 02115
    Eterna is focused on developing advanced therapies using state-of-the-art mRNA cell engineering technology.
  • Its mission is to realize the potential of cell engineering to provide patients with transformational new medicines.
  • Eterna has multiple next-generation cell and gene-editing therapies in preclinical development for various indications.

Eterna Therapeutics Completes Name Change, Acquires Option to License iPSC-Derived NK and T Cell Therapies from Exacis Biotherapeutics

Retrieved on: 
Monday, October 17, 2022
SAN, Method, U.S. Securities and Exchange Commission, Drug Quality and Security Act, Communication, RNA transfection, Therapy, ERNA, Growth, Cell engineering, Virus, Annual report, Society, Cell, Securities Exchange Act of 1934, Patient, Gene, Gene editing, Securities Act of 1933, Nasdaq, Technology, Cancer, Canadian Aviation Regulations, Private Securities Litigation Reform Act, Immune system, Company, Lymphatic system, TCR, CEO, GLOBE, Interim, Ink, Genome, NK, DNA, IPS, Forward-looking statement, Terminology, COVID-19, Sumathi Best Television Current Reporting Award, Engineering, Vaccine, Eterna

SAN DIEGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a biopharmaceutical company using advanced cell engineering technology to develop transformational new medicines, today announced it has entered into an option agreement with Exacis Biotherapeutics Inc. (“Exacis”) granting Eterna the right to negotiate an exclusive, worldwide license to develop and commercialize up to four iPS cell-derived natural killer cell (“iNK”) and/or T cell (“iT”) programs for hematologic malignancies and solid tumors.

Key Points: 
  • Exacis technology includes high-yield manufacturing processes and the ability to add advanced targeting molecules, including CARs and TCRs.
  • We are thrilled to partner with Eterna on these exciting programs, said Gregory Fiore, M.D., President and CEO of Exacis.
  • We look forward to working with Eterna to bring these novel next-generation iNK and iT cell therapies to patients with cancer who need new treatment options.
  • Under the agreement, Eterna and Exacis have until December 31, 2022 to negotiate and execute a license agreement.

EXACIS BIOTHERAPEUTICS GRANTS ETERNA THERAPEUTICS AN OPTION TO LICENSE UP TO FOUR ALLOGENEIC IPSC-DERIVED NK AND T CELL THERAPIES

Retrieved on: 
Monday, October 17, 2022
Method, RNA transfection, Therapy, Cell engineering, Virus, Neoplasm, Antibody, Patient, Genetic engineering, Cancer, Immune system, Company, Interim, Eterna, NK, DNA, Engineering, Video game console, Vaccine

The option agreement provides Exacis and Eterna until December 31, 2022 to negotiatethe licenseagreement.

Key Points: 
  • The option agreement provides Exacis and Eterna until December 31, 2022 to negotiatethe licenseagreement.
  • Dr. Dimitri Goundis, Exacis' Chief Business Officer commented, "Exacis is committed to using its powerful platform to produce safe and effective immune cell therapies for cancer.
  • Exacis' allogeneic engineered cell therapies, ExaNK and ExaCAR-NK,are designed to be used alone or in combination with antibodies or NK cell engagers for superior performance.For more information, please visit www.exacis.com .
  • Eterna has multiple next-generation cell and gene-editing therapies in preclinical development for various indications.For more information, please visit www.eternatx.com .

SOLVE FSHD invests US$10 Million in Vita Therapeutics

Retrieved on: 
Thursday, October 13, 2022
FSHD, SOLVE, Therapy, Life, Cell engineering, New Drug Application, US Foods, Facioscapulohumeral muscular dystrophy, Patient, Biotechnology, LGMD2A, Research, Johns Hopkins University, Technology, Food, Muscular dystrophy, Lululemon Athletica, Company, IPSC, Genetics, GLOBE, Cancer, Pharmaceutical industry, Dietary supplement

Chip Wilson, founder of lululemon athletica and SOLVE FSHD said, Living with FSHD for over 30 years, my upper body muscles are quite wasted.

Key Points: 
  • Chip Wilson, founder of lululemon athletica and SOLVE FSHD said, Living with FSHD for over 30 years, my upper body muscles are quite wasted.
  • In addition to Solve FSHD joining, other new investors included Riptide Ventures and Cedars Sinai, which participated alongside TEDCO and other existing investors.
  • SOLVE FSHD is funding innovative biotech and biopharma research and development activities that accelerate novel treatments for Facioscapulohumeral muscular dystrophy (FSHD).
  • He has committed $100 million of his own money to create SOLVE FSHD and kick-start funding into projects that fit the organizations mission: accelerate research into new therapies and find a cure for the disorder by 2027. https://solvefshd.com/
    For early-stage companies, contact Solve FSHD at [email protected].

Inceptor Bio and Avectas Announce Collaboration to Improve Manufacturing of CAR-T Cell Therapies for the Treatment of Solid Tumors

Retrieved on: 
Wednesday, October 12, 2022
Research Triangle Park, Cell engineering, Biotechnology, Cell, Electroporation, Technology, Tumor microenvironment, TimeSplitters: Future Perfect, Doctor of Philosophy, CEO, Cell membrane, Cancer, Triangle Park (Quezon City), Vaccine

MORRISVILLE, N.C. and DUBLIN, Oct. 12, 2022 /PRNewswire/ -- Inceptor Bio, a cell therapy biotechnology company and Avectas, a cell engineering technology leader, announce their collaboration to improve the development and manufacturing of next-generation CAR-T cell therapies for the treatment of solid tumors.

Key Points: 
  • MORRISVILLE, N.C. and DUBLIN, Oct. 12, 2022 /PRNewswire/ -- Inceptor Bio , acell therapy biotechnology company and Avectas , a cell engineering technology leader, announce their collaboration to improve the development and manufacturing of next-generation CAR-T cell therapies for the treatment of solid tumors.
  • By combining Avectas' SOLUPORE delivery with Inceptor Bio's CAR-T cell therapy platform, the engineered cells have the potential for improved performance and efficacy.
  • This collaboration with Avectas is part of our strategy of advancing Inceptor Bio's next-generation cell therapy platform focused on multiple novel mechanisms to address solid tumors," saidShailesh Maingi, Founder and CEO of Inceptor Bio.
  • "Avectas is delighted to collaborate with Inceptor Bio to leverage the benefits of the SOLUPORE delivery platform for solid tumor CAR-T cell therapies," said Michael Maguire, PhD, CEO of Avectas.

Inceptor Bio and Avectas Announce Collaboration to Improve Manufacturing of CAR-T Cell Therapies for the Treatment of Solid Tumors

Retrieved on: 
Wednesday, October 12, 2022
Research Triangle Park, Cell engineering, Biotechnology, Cell, Electroporation, Technology, Tumor microenvironment, TimeSplitters: Future Perfect, Doctor of Philosophy, CEO, Cell membrane, Cancer, Triangle Park (Quezon City), Vaccine

MORRISVILLE, N.C. and DUBLIN, Oct. 12, 2022 /PRNewswire/ -- Inceptor Bio, a cell therapy biotechnology company and Avectas, a cell engineering technology leader, announce their collaboration to improve the development and manufacturing of next-generation CAR-T cell therapies for the treatment of solid tumors.

Key Points: 
  • MORRISVILLE, N.C. and DUBLIN, Oct. 12, 2022 /PRNewswire/ -- Inceptor Bio , acell therapy biotechnology company and Avectas , a cell engineering technology leader, announce their collaboration to improve the development and manufacturing of next-generation CAR-T cell therapies for the treatment of solid tumors.
  • By combining Avectas' SOLUPORE delivery with Inceptor Bio's CAR-T cell therapy platform, the engineered cells have the potential for improved performance and efficacy.
  • This collaboration with Avectas is part of our strategy of advancing Inceptor Bio's next-generation cell therapy platform focused on multiple novel mechanisms to address solid tumors," saidShailesh Maingi, Founder and CEO of Inceptor Bio.
  • "Avectas is delighted to collaborate with Inceptor Bio to leverage the benefits of the SOLUPORE delivery platform for solid tumor CAR-T cell therapies," said Michael Maguire, PhD, CEO of Avectas.

Capstan Therapeutics Announces Appointment of Athena Countouriotis, M.D., as Board Chair and Strengthens Leadership Team with Key Appointment

Retrieved on: 
Wednesday, October 12, 2022
Stem Cells, Biotechnology, Other Health, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Genetics, Science, LinkedIn, CA, Sunitinib, Therapy, RNA transfection, Bayer, Sale, Cell engineering, Autoimmune disease, Ambit, Athena, Chairperson, Pfizer, Investment, Patient, Biotechnology, Coronavirus Scientific Advisory Board (Turkey), Gene editing, SM-102, Tolerx, Leal, Technology, University, Daiichi Sankyo, Company, Acquisition, Ambit Biosciences, Turning Point, Board, CEO, Adverum Biotechnologies, Eli Lilly, Immunotherapy, RA, Fibrosis, Regenerative medicine, Bristol Myers Squibb, Polaris Partners, DVM, Degenerative disease, Engineering, Management, Pharmaceutical industry, Capstan

We are thrilled Athena will be leading our Board and providing senior counsel to our team from her deep experience leading the development of multiple development programs to approval.

Key Points: 
  • We are thrilled Athena will be leading our Board and providing senior counsel to our team from her deep experience leading the development of multiple development programs to approval.
  • She also serves on the Board of Directors of Iovance Biotherapeutics, Passage Bio, Recludix Pharma and Leal Therapeutics.
  • He is a member of the Board of Directors of Bright Peak and the Scientific Advisory Board of Avilar.
  • Capstan Therapeutics is advancing precision in vivo cell engineering to develop therapeutics for a broad range of disease categories with unmet or underserved clinical need.

Vita Therapeutics Closes $31 Million Series B Financing to Develop Cell Therapies for Neuromuscular Diseases and Cancers

Retrieved on: 
Wednesday, October 12, 2022
Stem Cells, Biotechnology, Other Health, Health, Pharmaceutical, Oncology, Other Science, Research, Genetics, Science, Clinical Trials, Quality of life, LinkedIn, Muscle, Chip, SOLVE, Disease, Therapy, MS, IND, Cell engineering, Autosome, US Foods, Muscle weakness, Patient, Facioscapulohumeral muscular dystrophy, Gene editing, Biotechnology, LGMD2A, Twitter, Wasting, HIV disease progression rates, Walking, Research, Vita, Johns Hopkins University, CAR, Technology, Food, Muscular dystrophy, Lululemon Athletica, Company, Disorder, Health, Facial muscles, LGMD, Weakness, IPSC, Doctor of Philosophy, Adult, Immunotherapy, Genetics, Atrophy, Ageing, Ascending limb of loop of Henle, Cancer, Limb–girdle muscular dystrophy, Pharmaceutical industry, Dietary supplement, Vaccine, FSHD

Vita Therapeutics , a cell engineering company harnessing the power of genetics to develop novel cellular therapies to treat muscular dystrophies and cancers, today announced the completion of a $31 million Series B financing.

Key Points: 
  • Vita Therapeutics , a cell engineering company harnessing the power of genetics to develop novel cellular therapies to treat muscular dystrophies and cancers, today announced the completion of a $31 million Series B financing.
  • Vita Therapeutics current pipeline includes lead program, VTA-100 for the treatment of LGMD2A, VTA-120 for the treatment of FSHD, and VTA-300 targeting multiple cancers.
  • Vita Therapeutics is a biotechnology company developing state-of-the-art cellular therapeutics for the treatment of debilitating neuromuscular diseases and cancers.
  • Vita Therapeutics uses induced pluripotent stem cell (iPSC) technology to engineer specific cell types designed to replace those that are defective in patients.

Brooklyn ImmunoTherapeutics Announces Name Change to Eterna Therapeutics and Provides Corporate Updates

Retrieved on: 
Tuesday, October 11, 2022
SAN, Method, U.S. Securities and Exchange Commission, Securities Act of 1933, Communication, RNA transfection, Growth, Cell engineering, Annual report, Gene editing, Research, Nasdaq, Technology, Private Securities Litigation Reform Act, Company, Securities Exchange Act of 1934, GLOBE, Interim, Forward-looking statement, Eterna, Terminology, COVID-19, Sumathi Best Television Current Reporting Award, Pharmaceutical industry

SAN DIEGO, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (“Brooklyn” or the “Company”), today announces that it is changing its name to Eterna Therapeutics Inc. (“Eterna”) to reflect its focus on developing advanced therapies using its extensively patented in-licensed mRNA cell engineering technologies. The name change will be effective Monday, October 17, 2022. The Company’s common stock will trade on The Nasdaq Global Market under the new ticker symbol “ERNA”. The new ticker symbol, together with a one-for-twenty consolidation of the Company’s common stock, will become effective at the open of the market on October 17, 2022.

Key Points: 
  • The Companys common stock will trade on The Nasdaq Global Market under the new ticker symbol ERNA.
  • The new ticker symbol, together with a one-for-twenty consolidation of the Companys common stock, will become effective at the open of the market on October 17, 2022.
  • Eternas vision is to transform medicine by unlocking the potential of revolutionary cell engineering technology, said Matt Angel, Ph.D., Interim Chief Executive Officer of Brooklyn.
  • Eterna is well positioned to build on more than a decade of groundbreaking research by our technology partner, Factor Bioscience.